Cargando…
The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902)
BACKGROUND: The aim of this study was to evaluate the efficacy and safety of CapeOX plus bevacizumab with a planned oxaliplatin stop-and-go strategy in Japanese patients with metastatic colorectal cancer (mCRC). METHODS: Patients with untreated mCRC were treated with 4 cycles of CapeOX plus bevacizu...
Autores principales: | Nakayama, Goro, Ishigure, Kiyoshi, Yokoyama, Hiroyuki, Uehara, Keisuke, Kojima, Hiroshi, Ishiyama, Akiharu, Hayashi, Naomi, Takano, Nao, Hattori, Norifumi, Kobayashi, Daisuke, Tanaka, Chie, Hayashi, Masamichi, Kanda, Mitsuro, Yamada, Suguru, Sugimoto, Hiroyuki, Koike, Masahiko, Fujiwara, Michitaka, Fujii, Tsutomu, Murotani, Kenta, Ando, Yuichi, Kodera, Yasuhiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379705/ https://www.ncbi.nlm.nih.gov/pubmed/28376737 http://dx.doi.org/10.1186/s12885-017-3245-1 |
Ejemplares similares
-
The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801)
por: Nakayama, Goro, et al.
Publicado: (2012) -
Phase II study of capecitabine plus oxaliplatin (CapOX) as adjuvant chemotherapy for locally advanced rectal cancer (CORONA II)
por: Hattori, Norifumi, et al.
Publicado: (2019) -
A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902)
por: Ogata, Yutaka, et al.
Publicado: (2015) -
Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C(3)) study
por: Nagasaka, Takeshi, et al.
Publicado: (2016) -
Effect of bevacizumab plus XELOX (CapeOX) chemotherapy on liver natural killer cell activity in colorectal cancer with resectable liver metastasis
por: Hirata, Fumihiro, et al.
Publicado: (2018)